The National Pharmaceutical Pricing Authority (NPPA) has announced the retail price for a new drug, i.e., Cilnidipine and Telmisartan tablets. This order was published on February 7, 2025.
This decision follows a review order from the Department of Pharmaceuticals (DOP) and is made under the Drugs (Prices Control) Order, 2013 (DPCO, 2013).
Retail Price Announced
The NPPA has fixed the retail price for the following formulation:
- Cilnidipine (20mg) + Telmisartan (40mg) Tablets: ₹14.15 per tablet (exclusive of GST)
The price applies to M/s Akums Drugs & Pharmaceuticals Ltd. (manufacturer) and M/s Glenmark Pharmaceuticals Limited (marketing company).
Guidelines for the Manufacturer
These manufacturers may revise the retail price mentioned above. Goods and Services Tax can be added only if it is actually paid or payable to the government.
The price for a pack of the formulation must be calculated according to DPCO, 2013, provisions. The manufacturer must issue a price list (Form-V) to the NPPA (via IPDMS), State Drug Controller, and dealers.
Retailers and dealers must prominently display the price list.
The retail price applies specifically to the named manufacturer and marketer for this generic/branded formulation, provided all statutory requirements (including manufacturing license permission) are met.
Failure to comply with the notified price can result in the recovery of the overcharged amount with interest, under the DPCO, 2013, and the Essential Commodities Act, 1955.
Any previous price orders for this specific formulation, strength, and manufacturer/marketing company are superseded by this new notification.
Key Takeaway
This notification sets a clear price point for this specific combination drug, ensuring its availability at a regulated price. The guidelines aim to ensure transparency and compliance across the supply chain, protecting consumer interests.
